Hubbard A L, Doris C P, Thompson A M, Chetty U, Anderson T J
Department of Pathology, University of Edinburgh, Medical School, UK.
Br J Cancer. 1994 Sep;70(3):434-9. doi: 10.1038/bjc.1994.323.
Tissues from 323 methacarn-fixed and paraffin-embedded breast cancers were assessed for c-erbB-2 gene amplification by differential polymerase chain reaction (dPCR). The sensitivity of dPCR was ascertained using cell lines with c-erbB-2 amplification, and the relationship between dPCR ratio value and gene copy number was established. In clinical material the technique was not affected by the DNA contribution of normal tissue elements or by cancer DNA ploidy change. c-erbB-2 gene amplification was detected in 55% of invasive cancers and in 66% of in situ cancers. c-erbB-2 protein overexpression in breast cancer cells, as determined by specific immunohistochemistry, was only detected in 11% of invasive cancers and 43% of in situ cancers. Comparisons show that a substantial number of cancers with c-erbB-2 amplification lack detectable protein overexpression. This illustrates the complex nature of c-erbB-2 gene disregulation in cancer and suggests that multiple combinations of biological events and consequences are possible.
采用差异聚合酶链反应（dPCR）对323例经甲醇-氯仿固定及石蜡包埋的乳腺癌组织进行c-erbB-2基因扩增评估。使用具有c-erbB-2扩增的细胞系确定dPCR的敏感性，并建立dPCR比值与基因拷贝数之间的关系。在临床材料中，该技术不受正常组织成分的DNA贡献或癌DNA倍性变化的影响。在55%的浸润性癌和66%的原位癌中检测到c-erbB-2基因扩增。通过特异性免疫组织化学测定，乳腺癌细胞中c-erbB-2蛋白过表达仅在11%的浸润性癌和43%的原位癌中检测到。比较表明，大量具有c-erbB-2扩增的癌症缺乏可检测到的蛋白过表达。这说明了癌症中c-erbB-2基因失调的复杂性质，并表明生物事件和后果可能存在多种组合。
